Conversely, Nifurtimox reduces STAT1 phosphorylation by binding to the Tyr701 site on STAT1, a mechanism that decreases CXCR2+ neutrophil recruitment and alleviates tumor burden in pancreatic cancers, providing a novel avenue for therapeutic intervention (170).In colorectal cancers, Wedelolactone has been observed to enhance the IFN-γ/STAT1 signaling, reinforcing its antitumor effects by inhibiting the dephosphorylation of STAT1 by T-cell protein tyrosine phosphatase (TCPTP). Here, STAT1 is linked to pancreatic neoplasm.